We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Use of Molecular Assays for HIAs Growing Rapidly

By LabMedica International staff writers
Posted on 07 Oct 2010
Print article
Image: A conceptual visualization of the methicillin-resistant staphylococcus aureus (MRSA) bacteria (photo courtesy Medical RF.com).
Image: A conceptual visualization of the methicillin-resistant staphylococcus aureus (MRSA) bacteria (photo courtesy Medical RF.com).
Molecular tests that can quickly identify hospital- acquired infections (HIAs) are rapidly becoming more popular.

The most serious HAIs include methicillin resistant Staphylococcus aureus (MRSA), Clostridium difficile, which causes an intestinal infection), Vancomycin-resistant Enterococcus, linked with intestinal, skin and blood infections, and drug-resistant Acinetobacter, which can cause pneumonia, skin, and blood infections.

There are several approaches to HAI detection. On the conservative and least expensive side are chromogenic growth media that permit the selective growth of MRSA bacteria and produce a colored colony that is easily recognizable. On the more expensive side, there has been an explosion of user-friendly molecular assays that are widely accepted.

Kalorama Information (Rockville, MD, USA), a healthcare market research publisher, has reported that molecular tests that can quickly identify patients for isolation and treatment are being utilized despite their higher cost. Kalorama forecasts that revenues for molecular tests that detect HAIs will grow at 25% per year for the next five years.

"They are growing at four times the rate of the average IVD products,” said Shara Rosen, senior diagnostic analyst for Kalorama Information and the author of the report. "HAIs are a huge problem and this is an opportunity for the most logical tests to treat them.”

The advantage of these molecular tests is that they can provide highly sensitive rapid turnaround results. Cepheid (Sunnyvale, CA, USA), Becton Dickinson (BD; Franklin Lakes, CA, USA), and Seegene (Seoul, Korea) are among the companies with products used to test for HAIs.

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) estimates that HAIs affect nearly 2 million Americans annually, resulting in 90,000 deaths and up to US $6.5 billion in extra costs.

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:
Cepheid
Becton Dickinson
Seegene
Kalorama Information
U.S. Centers for Disease Control and Prevention


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more